- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.12. | Ernexa Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.12. | Ernexa Therapeutics: Aktie fällt trotz positiver Studiendaten | 2 | Investing.com Deutsch | ||
| 08.12. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer | 1 | GlobeNewswire (USA) | ||
| 03.12. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.12. | Ernexa Therapeutics appoints oncologist Dr. Winer to advisory board | 1 | Investing.com | ||
| 02.12. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG | 1 | GlobeNewswire (USA) | ||
| 11.11. | Ernexa Therapeutics Inc.: Ernexa Therapeutics to Present at Oxford Global's Cell 2025 | 2 | GlobeNewswire (USA) | ||
| 10.11. | Eterna Therapeutics reports Q3 results | 1 | Seeking Alpha | ||
| 10.11. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials | 106 | GlobeNewswire (Europe) | The Company's operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program... ► Artikel lesen | |
| 07.11. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor "What This Means" Platform | 1 | GlobeNewswire (USA) | ||
| 29.10. | Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer | 140 | PR Newswire | THE WOODLANDS, Texas, and CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization... ► Artikel lesen | |
| 29.10. | Ernexa Therapeutics stock soars after Cellipont manufacturing deal | 3 | Investing.com | ||
| 29.10. | Ernexa Therapeutics: Aktie schießt nach Produktionsvereinbarung mit Cellipont in die Höhe | 5 | Investing.com Deutsch | ||
| 01.10. | Ernexa Therapeutics Inc.: Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa | 1 | GlobeNewswire (USA) | ||
| 29.09. | Ernexa Therapeutics: Interview With President & CEO Sanjeev Luther About The Innovative Cell Therapy Company | 2 | pulse2.com | ||
| 29.09. | Ernexa Therapeutics Inc.: Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit | 1 | GlobeNewswire (USA) | ||
| 10.09. | Ernexa Therapeutics reports 51% reduction in operating expenses | 1 | Investing.com | ||
| 10.09. | Ernexa Therapeutics senkt operative Kosten um 51 % | 1 | Investing.com Deutsch | ||
| 10.09. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Provides Update on Operational Excellence and Performance | 259 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provided... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,740 | +0,77 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| DISC MEDICINE | 80,04 | -11,50 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,32 | +0,26 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,580 | +4,43 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,265 | -3,94 % | Cathie Wood's ARK sells Tesla stock, buys Coinbase and Recursion Pharmaceuticals | ||
| STRUCTURE THERAPEUTICS | 64,94 | +3,84 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| IMMUNOME | 21,400 | +7,21 % | Immunome-Aktie fällt nach Ankündigung einer Kapitalerhöhung über 400 Mio. US-Dollar | ||
| PRAXIS PRECISION MEDICINES | 272,85 | +1,33 % | Praxis Precision Medicines stock price target raised to $750 from $250 at Oppenheimer | ||
| OLEMA PHARMACEUTICALS | 27,830 | -9,44 % | From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? | LONDON (dpa-AFX) - The biotech sector continues to deliver headline-grabbing moves, with stocks surging to fresh highs and companies advancing pivotal trials, regulatory filings, and strategic... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,51 | +1,50 % | Apogee Therapeutics: Noch ein sharedealsPlus-Verdoppler! | Im Juli hatten wir mit der Aktie von Apogee Therapeutics einen Verdopplungskandidaten identifiziert. Jetzt, keine fünf Monate später, konnte die Aktie tatsächlich mehr als +100% zulegen. Ein weiterer... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,850 | +7,04 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| VERA THERAPEUTICS | 51,13 | +7,30 % | Vera Therapeutics stock price target raised to $66 by BofA Securities | ||
| ARCUTIS BIOTHERAPEUTICS | 28,050 | +0,95 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| BIONTECH | 79,00 | +1,28 % | Alarm bei Evotec! BioNTech und Vidac Pharma mit Erfolgen beim Kampf gegen Krebs! Analysten raten zum Kauf! | Bei Evotec läuten die Alarmglocken. Ein Großaktionär ist komplett beim deutschen Biotech-Unternehmen ausgestiegen. Dabei notiert das Wertpapier auf dem Niveau von 2016. Einen Meilenstein hat dagegen... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,600 | +4,17 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
Das Unternehmen ERNEXA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,040 (+3,17 %) liegt der Kurs bei 1,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.